ANP Peptide Sequence and Structure: The 28-Residue Ring and What It Fixes
This is a personal independent educational research site. All content consists of my personal study notes for academic reference only. It is NOT medical advice and cannot be used for disease diagnosis, treatment or clinical decision-making. This site is not affiliated with any peptide supplier or medical institution.
My notes on anp peptide sequence structure start from one fact: the circulating form is a 28-residue chain whose behaviour is dominated by a single covalent ring. Nearly everything I read about activity, stability and bench behaviour comes back to that ring. This page records how I read the primary sequence, and what I think it does and does not tell me.
The atrial natriuretic peptide literature usually writes the molecule as ANP(1-28) or alpha-ANP. The numbering assumes the 28-residue mature peptide, while longer precursor forms use a different frame. In my own archive I write the frame down explicitly, because a residue index without a frame is the most common source of confusion I run into when comparing two papers. The anp peptide sequence structure is short, but frame ambiguity makes it easy to misread.
What follows is literature reading, not a protocol. I am recording how the sequence and the ring are described in the primary papers, how the numbering is derived from the precursor, and which structural facts a plain residue listing leaves out. For the wider physiological framing I keep the ANP peptide research overview as my entry point.
The primary sequence of ANP(1-28), residue by residue
Human ANP(1-28) is written Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr. Twenty-eight residues, two cysteines at positions 7 and 23, and a high proportion of small residues in the middle of the chain. The full anp peptide sequence structure is short enough to hold in memory, which is one reason it gets quoted so freely in secondary sources.
I also keep the single-letter form, because most sequence tools expect it: SLRRSSCFGGRMDRIGAQSGLGCNSFRY. Read left to right the two cysteines sit sixteen residues apart, with six residues before the first and five after the second. That asymmetry, a long ring and a short C-terminal tail, is what the structure figures in the literature keep drawing, and it is the part of the anp peptide sequence structure I check first.
The Cys7-Cys23 ring and why it dominates the conformation
The disulfide bridge between Cys7 and Cys23 closes a 17-residue loop. In every structural account I have read, this loop is the defining feature of the anp peptide sequence structure: open it and the molecule loses most of its receptor activity. The cross-link takes a 28-residue chain that would otherwise sample a very large set of shapes and narrows the set considerably.
The conformational effect should not be overstated. A single disulfide does not freeze a peptide into one rigid shape. NMR work on atrial natriuretic peptide describes a ring with restricted but real flexibility, and tails that remain largely flexible in solution. What the cross-link does is shrink the conformational space, so the ensemble the molecule samples is much narrower than that of the reduced chain.
Truncation: what removing residues does
The truncation literature is the clearest evidence that the ring, not the tails, carries the activity. Shortening the C-terminal tail or trimming N-terminal residues shifts potency, but opening or deleting the ring collapses it. I read the truncation papers as a map of which parts of the anp peptide sequence structure are load bearing.
Fragments that keep the ring but lose the tails generally retain measurable receptor interaction, while linear or ring-opened analogues lose most of it. This is the pattern I return to whenever I evaluate a claim about a modified ANP sequence: the first question is whether the ring is intact, and the second is which tails remain. Read that way, the anp peptide sequence structure is a map of tolerated and untolerated change.
From proANP(1-126) to the circulating 28-mer
The 28-residue form does not come off the ribosome, and the anp peptide sequence structure quoted in papers is a processed fragment rather than a translated product. It is cut out of a larger precursor, proANP, which in human is 126 residues and appears in older papers as gamma-ANP. The mature sequence sits at the C-terminal end of the precursor, so numbering in the precursor frame and numbering in the mature frame are offset, and a residue carries two different numbers depending on the frame.
The cleavage step is attributed in the literature to a membrane-associated serine protease, corin, acting in the atrial myocyte. I record this because the same cleavage logic explains why N-terminally extended, proANP-derived peptides appear in the literature with their own names and their own assays. When a paper reports an NT-proANP measurement it is reading the other half of the precursor, not the 28-mer.
Sequence conservation across species
Atrial natriuretic peptide is well conserved but not identical across the species I have looked at. Rat ANP differs from human ANP at a single position inside the ring, with isoleucine where the human sequence has methionine. That one substitution is why rat and human material are not interchangeable in my reading notes, and it is also why their masses differ by roughly eighteen daltons.
The residues that stay constant are the informative ones: the two cysteines, the ring glycines, and the C-terminal Phe-Arg-Tyr. Conservation of the cysteine positions across species is the comparative argument that the ring is functional rather than incidental. I read it as the strongest non-experimental support for reading the anp peptide sequence structure as a ring-first molecule, alongside my natriuretic peptide family notes.
What a sequence listing does not tell you
A sequence string is a residue sequence and nothing more. It does not encode the disulfide connectivity, the salt form, the counter-ion, the water content or the aggregation state. Every one of those changes how a sample of atrial natriuretic peptide behaves on the bench, and none of them appears in the letters. The anp peptide sequence structure on its own cannot distinguish them. This is the most useful caution I have taken from reading the primary literature.
Two samples with identical sequences can differ because one carries the correct ring and the other a scrambled one, or because one is an acetate salt and the other a trifluoroacetate salt, or because one has been through repeated freeze-thaw cycles. My record therefore always separates the phrase sequence as written from the phrase material as received. The distinction is set out in my editorial notes and in my core page on anp peptide.
References
- PubMed search: atrial natriuretic peptide primary sequence ANP(1-28)
- PubMed search: atrial natriuretic peptide disulfide ring structure activity
- PubMed search: proANP 1-126 processing corin cleavage atrial peptide
- PubMed search: atrial natriuretic peptide sequence conservation species comparison
References are recorded as text. The record links to no external domain: each entry can be re-run in any public bibliographic database.
Frequently Asked Questions
How many residues does ANP(1-28) contain and where are the cysteines?
ANP(1-28) is 28 residues long in the mature numbering frame. The two cysteines sit at positions 7 and 23 and are joined by a single disulfide bond that closes a 17-residue ring. Everything before position 7 is the N-terminal tail and everything after position 23 is the C-terminal tail, which ends in Tyr. When I copy a sequence into the record I also copy the frame, because precursor numbering runs to 126 residues and the same residue carries two different numbers depending on which frame a paper uses.
Why does the ring matter so much for receptor activation?
The ring constrains the chain, so the binding surface is presented at a lower entropic cost than a flexible peptide would pay. Structural and analogue work on atrial natriuretic peptide consistently reports that ring-opened or alkylated forms lose far more activity than tail-truncated forms. My reading of the anp peptide sequence structure is that the ring sets the geometry and the tails modulate it, which is why I take ring integrity as the first thing to establish before comparing any two sequence variants.
Is the rat sequence the same as the human sequence?
Not quite. The rat mature 28-mer differs from the human one at a single position inside the ring, with isoleucine in place of the human methionine, which makes the rat molecule lighter by roughly eighteen daltons. The tails vary more between species than the ring does. The cysteine positions and the C-terminal Phe-Arg-Tyr are conserved across the species I have recorded, which is the comparative evidence that the ring is functional.
What does a plain sequence listing leave out?
A residue sequence says nothing about disulfide connectivity, salt form, counter-ion, residual water, aggregation state or purity. Two materials with the same letters can behave differently on the bench for any of those reasons. It also does not say which numbering frame is in use. In my notes I keep the sequence as written strictly separate from the material as received, and I record the method used to confirm the mass and the ring.
Related Notes
Question about how this archive is compiled? The editorial desk answers questions about sources, attribution and correction requests.
Contact the editorial desk